<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539253</url>
  </required_header>
  <id_info>
    <org_study_id>J06108</org_study_id>
    <secondary_id>NA_00003943</secondary_id>
    <nct_id>NCT00539253</nct_id>
  </id_info>
  <brief_title>Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.</brief_title>
  <acronym>TACE</acronym>
  <official_title>Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if using the contrast agent MultiHance can be used to
      show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial
      Chemoembolization (TACE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast
      material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is
      believed that using MultiHance may be able to help doctors tell normal liver cells apart from
      active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve
      the way patients with hepatocellular carcinoma are managed clinically.

      We hypothesize that the Multi-Hance contrast material will provide better image definition of
      treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast
      agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nodule Size</measure>
    <time_frame>3 months</time_frame>
    <description>Maximal nodule size measured in centimeters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nodule Enhancement</measure>
    <time_frame>3 month</time_frame>
    <description>Percent area of nodule with enhancement</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Gadobenate Dimeglumine (Multi Hance)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadobenate dimeglumine (MultiHance)</intervention_name>
    <description>The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.</description>
    <arm_group_label>Gadobenate Dimeglumine (Multi Hance)</arm_group_label>
    <other_name>MultiHance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional
             radiology clinic who are scheduled for TACE.

          -  International Normalized Ratio (INR) &lt;1.4

          -  Platelet count &gt; 80,000

        Exclusion Criteria:

          -  Contraindications to TACE procedure

          -  Unable to have an MRI Scan

          -  Allergy or hypersensitivity reactions to gadolinium or any other ingredients,
             including benzyl alcohol

          -  Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias

          -  Known clinical hypersensitivity or a history of asthma or allergic respiratory
             disorders

          -  Patients with advanced renal failure (those currently requiring dialysis or with a
             Glomerular Filtration Rate&lt;15cc/min)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ihab Kamel</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <results_first_submitted>October 12, 2016</results_first_submitted>
  <results_first_submitted_qc>August 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2017</results_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>January, 2008 to May, 2012
People with hepatocellular carcinoma who were candidates for TACE who were referred to Johns Hopkins Hospital.</recruitment_details>
      <pre_assignment_details>none observed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gadabenate Dimeglumine( Multihance)</title>
          <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MRI imaging for both the baseline and 1 month f/u studies.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gadobenate Dimeglumine (Multi Hance)</title>
          <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" lower_limit="43" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Percentage of enhancement changes observed using Triple-phase MultiHance-enhanced MRI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nodule Size</title>
        <description>Maximal nodule size measured in centimeters</description>
        <time_frame>3 months</time_frame>
        <population>The number of participants analyzed reflects the number of participants for whom data was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Multihance</title>
            <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.</description>
          </group>
        </group_list>
        <measure>
          <title>Nodule Size</title>
          <description>Maximal nodule size measured in centimeters</description>
          <population>The number of participants analyzed reflects the number of participants for whom data was available.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nodule Enhancement</title>
        <description>Percent area of nodule with enhancement</description>
        <time_frame>3 month</time_frame>
        <population>Number of participants analyzed reflects the number of participants for whom data was available</population>
        <group_list>
          <group group_id="O1">
            <title>Multihance</title>
            <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.</description>
          </group>
        </group_list>
        <measure>
          <title>Nodule Enhancement</title>
          <description>Percent area of nodule with enhancement</description>
          <population>Number of participants analyzed reflects the number of participants for whom data was available</population>
          <units>percent enhancement</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gadobenate Dimeglumine (Multi Hance)</title>
          <description>If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
gadobenate dimeglumine (MultiHance): The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ihab R. Kamel, M.D. PhD</name_or_title>
      <organization>Johns Hopkins Hospital</organization>
      <phone>410-955-4567</phone>
      <email>ikamel@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

